Senate Democrats say RFK Jr.'s divestment plans are 'plainly inadequate' ahead of Tuesday vote

Zachary Brennan

Senior Editor

Democrats in the Senate Finance Committee are calling Robert F. Kennedy Jr.’s new divestment plans to his son “plainly inadequate” ahead of a Tuesday vote …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Senate Democrats say RFK Jr.'s divestment plans are 'plainly inadequate' ahead of Tuesday vote

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Drugmakers seize on biomarkers to test the FDA's rare disease shift

Biogen’s revised research strategy is to avoid becoming obsolete, top exec says

Updated: Drug prices likely to soar due to Trump tariffs, pharma bodies warn

Exclusive: German biotech declares Phase 2 win for non-opioid drug for neuropathic pain

Irish startup reports mid-stage victory for short-acting psychedelic drug in depression

Pfizer says new colorectal cancer data could support full approval of Braftovi

Sen­ate De­moc­rats say RFK Jr.'s di­vest­ment plans are 'plain­ly in­ad­e­quate' ahead of Tues­day vote

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

Drug­mak­ers seize on bio­mark­ers to test the FDA's rare dis­ease shift

Bio­gen’s re­vised re­search strat­e­gy is to avoid be­com­ing ob­so­lete, top ex­ec says

Up­dat­ed: Drug prices like­ly to soar due to Trump tar­iffs, phar­ma bod­ies warn

Ex­clu­sive: Ger­man biotech de­clares Phase 2 win for non-opi­oid drug for neu­ro­path­ic pain

Irish start­up re­ports mid-stage vic­to­ry for short-act­ing psy­che­del­ic drug in de­pres­sion

Pfiz­er says new col­orec­tal can­cer da­ta could sup­port full ap­proval of Braftovi

Senate Democrats say RFK Jr.'s divestment plans are 'plainly inadequate' ahead of Tuesday vote

Drugmakers seize on biomarkers to test the FDA's rare disease shift

Biogen’s revised research strategy is to avoid becoming obsolete, top exec says

Updated: Drug prices likely to soar due to Trump tariffs, pharma bodies warn

Exclusive: German biotech declares Phase 2 win for non-opioid drug for neuropathic pain

Irish startup reports mid-stage victory for short-acting psychedelic drug in depression

Pfizer says new colorectal cancer data could support full approval of Braftovi